Aoife Carr - Concepedia

Author

Aoife Carr

Royal College of Surgeons in Ireland

Also Known As

A. Carr, A. H. CARR, A. H. Carr, Aoife Carr, Carr, Aoife

Publications

347

Citations

H-Index

Concepts

All Affiliations

Royal College of Surgeons in Ireland Beaumont Hospital St. Vincent's University Hospital St. James's Hospital University College Dublin

About

Aoife Carr is an author at Royal College of Surgeons in Ireland specializing in breast cancer, radiation oncology, and tumor microenvironment.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	68
2	Cancer Therapeutics	2	2	68
3	Cell Biology	1	1	48
4	Pathology	1	1	20
5	Cancer Genetics	1	1	20

Aoife Carr

Publications

328

Citations

H-Index

Page 1

	Year	Citations
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib Naomi Elster, Mattia Cremona, Clare Morgan, Breast Cancer Research and Treatment Radiation OncologyBreast OncologyHer2-targeted Therapies TrastuzumabPreclinical EvaluationMedicine	2014	48
The validity and value of histological and cytological classifications of lung cancer John D. Reid, Aoife Carr Cancer	1961	37
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer M. Janusz Mezynski, Angela M. Farrelly, Mattia Cremona, Journal of Translational Medicine	2021	37
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies Sinéad Toomey, Alex J. Eustace, Joanna Fay, Breast Cancer Research	2017	34
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib John J. O’Shea, Mattia Cremona, Clare Morgan, Oncotarget	2017	21
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH) Damien Côté, Alex J. Eustace, Sinéad Toomey, PLoS ONE Breast OncologyErbb3 SnpsMedicinePathologyCancer Genomics	2018	20
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer Sinéad Toomey, Stephen F. Madden, Simon J. Furney, Oncotarget	2016	19
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER” Niamh M. Keegan, Simon J. Furney, Janice M. Walshe, Cancers	2021	19
Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer Cha Len Lee, Mattia Cremona, Angela M. Farrelly, Cancer Biology & Therapy	2023	19
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples Sinéad Toomey, Aoife Carr, M. Janusz Mezynski, Journal of Translational Medicine	2020	18

Page 1